COPD Pathophysiology - The Inflamed Airway
- Chronic inflammation triggered by noxious particles (tobacco smoke, pollution) recruits key inflammatory cells: neutrophils, macrophages, and CD8+ T-cells.
- This leads to two core pathologic processes:
- Parenchymal Destruction (Emphysema): An imbalance of ↑proteases (like neutrophil elastase) and ↓antiproteases (like α1-antitrypsin) destroys alveolar walls, causing loss of elastic recoil.
- Small Airway Disease: Inflammation and oxidative stress lead to goblet cell hyperplasia (chronic bronchitis) and peribronchiolar fibrosis, which narrows the airway.

⭐ The primary site of airflow limitation in early COPD is the small conducting airways (<2 mm in diameter), often preceding significant alveolar destruction.
COPD Diagnosis - The Breathless Patient
-
Clinical Suspicion: Based on symptoms (progressive dyspnea, chronic cough, sputum) & risk factor exposure (tobacco smoke, occupational dusts).
- History: >20 pack-year smoking history is a classic risk.
- Exam findings: Barrel chest, pursed-lip breathing, decreased breath sounds.
-
Spirometry: Gold standard for diagnosis. Must be performed post-bronchodilator.
- Diagnostic Hallmark: Fixed airflow obstruction with FEV1/FVC < 0.70.
⭐ In young patients (<45 years) or non-smokers with a family history, screen for Alpha-1 Antitrypsin (AAT) deficiency, which causes basilar-predominant emphysema.

COPD Staging - The GOLD Standard
-
Staging begins after a post-bronchodilator FEV1/FVC < 0.70 confirms diagnosis. Airflow limitation severity (spirometric grade) is based on FEV1:
- GOLD 1 (Mild): FEV1 ≥ 80% predicted
- GOLD 2 (Moderate): 50% ≤ FEV1 < 80%
- GOLD 3 (Severe): 30% ≤ FEV1 < 50%
- GOLD 4 (Very Severe): FEV1 < 30%
-
The refined ABCD assessment tool guides therapy by combining symptom burden (mCAT/CCQ scores) with exacerbation risk.
⭐ Treatment decisions are primarily guided by the patient's ABCD assessment group, not the spirometric grade alone.
High‑Yield Points - ⚡ Biggest Takeaways
- COPD is characterized by persistent, irreversible airflow limitation, with cigarette smoking as the number one risk factor.
- The core pathophysiology involves a protease-antiprotease imbalance, leading to alveolar destruction (emphysema).
- Spirometry is required for diagnosis, confirming a post-bronchodilator FEV1/FVC ratio < 0.7.
- Suspect α1-antitrypsin deficiency in young patients (<45 years) with panacinar emphysema and no smoking history.
- Unlike asthma, the airflow obstruction is not fully reversible with bronchodilators.
Continue reading on Oncourse
Sign up for free to access the full lesson, plus unlimited questions, flashcards, AI-powered notes, and more.
CONTINUE READING — FREEor get the app